Frost & Sullivan: New Testing Options Bring Prenatal Testing Market to the Forefront in the U.S.
MOUNTAIN VIEW, Calif., June 5, 2012 /PRNewswire/ — Prenatal testing is an available choice for pregnant women around the world to obtain information at their discretion about the fetus they are carrying. Women may choose to detect chromosome abnormalities in the fetus. For example, mothers-to-be are often told by their OBGYNs about the increased risk of chromosomal abnormality with advanced maternal age. In the United States, the trend of increasing maternal age for women may also increase the use of prenatal tests.
Analysis from Frost & Sullivan’s (http://www.clinicaldiagnostics.frost.com) Strategic Analysis of the U.S. Prenatal Testing Market research finds that the market earned revenues of $1.28 billion in 2010 and estimates this to reach $1.59 billion in 2017. In this analysis, Frost & Sullivan’s in vitro diagnostic (IVD) industry analysts thoroughly examine the following market segments: maternal serum screen, nuchal translucency (NT) ultrasound, karyotype, prenatal fluorescent in situ hybridization (FISH), and prenatal chromosomal array.
If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at firstname.lastname@example.org, with your full name, company name, title, telephone number, company email address, company Web site, city, state and country.
“Prenatal diagnostic companies aim to develop tests that give women the information they want about their pregnancy,” said Frost & Sullivan Industry Analyst Winny Tan. “Should pregnant women elect prenatal testing, these companies understand that is critical for the test results to be as conclusive and reliable as possible as this is a sensitive and very personal area.”
Highly perceptive testing methods are available in prenatal testing. Prenatal chromosomal array detects serious chromosomal abnormalities at a higher resolution than traditional karyotyping. While prenatal microarray requires an invasive procedure, non-invasive prenatal diagnostics (NIPD) on the other hand, does not require an amniocentesis or chorionic villus sampling (CVS). Several companies are focused on bringing NIPD to the market.
“This industry is witnessing major technological developments,” said Tan. “Cutting-edge techniques like comparative genomic hybridization (ArrayCGH) microarray and sequence analysis of circulating fetal DNA found in maternal blood are being applied to prenatal testing by companies. Included in Frost & Sullivan research findings is that 60 to 70 percent of all pregnancies in the United States receive a maternal serum screen. A much smaller group undergoes diagnostic testing that is invasive.”
This Frost & Sullivan research is an objective overview of the trends and dynamics of an industry and its patients within the United States. Frost & Sullivan acknowledges that the market exists, but makes no other statements or opinions.
Strategic Analysis of the U.S. Prenatal Testing Market is part of the Life Sciences Growth Partnership Services program, which also includes research in the following markets: Analysis of the U.S. Clinical Laboratory Market, European Genetic Testing and Screening Services Market, Overview of the Orphan Diseases and Drugs Space in Sub-Saharan Africa, Competitive Landscape for the United States Molecular Quality Controls Market, and Strategic Analysis of the U.S. Research Antibodies Market. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.
Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Strategic Analysis of the U.S. Prenatal Testing Market
Corporate Communications – North America
SOURCE Frost & Sullivan